Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Dabrafenib and Trametinib Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish High- and Low-Risk Patients with TNBC Your NCI: Top Priorities from AACR 2026 MOST POPULAR Seven Ways an Occupational Therapist Can Help Patients Recovering From Breast... April 30, 2021 First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with... February 14, 2023 Dear Prime Minister: “Please don’t delay action again, we’re counting on... October 16, 2020 Tovorafenib Approved for Some Children with Low-Grade Glioma May 28, 2024 Load more HOT NEWS Young Breast Cancer Survivor Killed in Hit and Run Crash Weeks... FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma Understanding the Risk of Second Cancers After CAR T-Cell Therapy
